IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

FDA Charges Ranbaxy with Falsifying Data at India Plant

11:11 AM MST | March 6, 2009 | DEEPTI RAMESH

The U.S. FDA has charged Ranbaxy Laboratories (Gurgaon, India) with falsifying data and test results in approved and pending drug applications at the company’s Paonta Sahib, India facility. The agency says it has stopped reviewing new or pending drug approval applications from the plant, which has been under an FDA import alert since last September for deviating from U.S. cGMP (CW, Sept. 22, 2008, p. 4). Ranbaxy says it will co-operate with FDA. Woodcock: ‘Companies must provide truthful and accurate information.’ Applications that are affected...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa